{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Syndécane-2 : Questions médicales les plus fréquentes",
"headline": "Syndécane-2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Syndécane-2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-14",
"dateModified": "2025-05-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Syndécane-2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Syndécanes",
"url": "https://questionsmedicales.fr/mesh/D053667",
"about": {
"@type": "MedicalCondition",
"name": "Syndécanes",
"code": {
"@type": "MedicalCode",
"code": "D053667",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.550.847"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Syndécane-2",
"alternateName": "Syndecan-2",
"code": {
"@type": "MedicalCode",
"code": "D053669",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Eok-Soo Oh",
"url": "https://questionsmedicales.fr/author/Eok-Soo%20Oh",
"affiliation": {
"@type": "Organization",
"name": "Department of Life Sciences, College of Natural Sciences, Ewha Womans University, Seoul 03760, Korea."
}
},
{
"@type": "Person",
"name": "Anett Hudák",
"url": "https://questionsmedicales.fr/author/Anett%20Hud%C3%A1k",
"affiliation": {
"@type": "Organization",
"name": "Pharmacoidea Ltd., H-6726 Szeged, Hungary."
}
},
{
"@type": "Person",
"name": "Tamás Letoha",
"url": "https://questionsmedicales.fr/author/Tam%C3%A1s%20Letoha",
"affiliation": {
"@type": "Organization",
"name": "Pharmacoidea Ltd., H-6726 Szeged, Hungary."
}
},
{
"@type": "Person",
"name": "Bohee Jang",
"url": "https://questionsmedicales.fr/author/Bohee%20Jang",
"affiliation": {
"@type": "Organization",
"name": "Department of Life Sciences, College of Natural Sciences, Ewha Womans University, Seoul 03760, Korea."
}
},
{
"@type": "Person",
"name": "Annamária Letoha",
"url": "https://questionsmedicales.fr/author/Annam%C3%A1ria%20Letoha",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, H-6725 Szeged, Hungary."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease.",
"datePublished": "2022-10-13",
"url": "https://questionsmedicales.fr/article/36229464",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-022-33780-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Experiences and Unmet Supportive Care Needs of Partners of Men Diagnosed With Prostate Cancer: A Meta-aggregation Systematic Review.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36480350",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/NCC.0000000000001172"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.",
"datePublished": "2022-10-07",
"url": "https://questionsmedicales.fr/article/36094042",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijc.34290"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative Performance of Deep Learning and Radiologists for the Diagnosis and Localization of Clinically Significant Prostate Cancer at MRI: A Systematic Review.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36294928",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/life12101490"
}
},
{
"@type": "ScholarlyArticle",
"name": "External Validation of Models for Prediction of Side-specific Extracapsular Extension in Prostate Cancer Patients Undergoing Radical Prostatectomy.",
"datePublished": "2022-09-21",
"url": "https://questionsmedicales.fr/article/36153227",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.euf.2022.09.006"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycoprotéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008562"
},
{
"@type": "ListItem",
"position": 6,
"name": "Syndécanes",
"item": "https://questionsmedicales.fr/mesh/D053667"
},
{
"@type": "ListItem",
"position": 7,
"name": "Syndécane-2",
"item": "https://questionsmedicales.fr/mesh/D053669"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Syndécane-2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Syndécane-2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Syndécane-2",
"description": "Comment diagnostiquer une anomalie de Syndécane-2 ?\nQuels examens sont recommandés pour le Syndécane-2 ?\nLe dosage sanguin est-il utile pour le Syndécane-2 ?\nQuels marqueurs sont associés au Syndécane-2 ?\nY a-t-il des tests spécifiques pour le Syndécane-2 ?",
"url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Prostatic+Hyperplasia&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Syndécane-2",
"description": "Quels symptômes sont liés à une dysfonction de Syndécane-2 ?\nLe Syndécane-2 affecte-t-il la croissance tumorale ?\nY a-t-il des signes cliniques associés au Syndécane-2 ?\nLe Syndécane-2 est-il lié à des maladies spécifiques ?\nComment le Syndécane-2 influence-t-il la signalisation cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Prostatic+Hyperplasia&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Syndécane-2",
"description": "Peut-on prévenir les anomalies de Syndécane-2 ?\nY a-t-il des mesures préventives spécifiques ?\nL'alimentation influence-t-elle le Syndécane-2 ?\nLe tabagisme affecte-t-il le Syndécane-2 ?\nL'exercice physique a-t-il un impact sur le Syndécane-2 ?",
"url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Prostatic+Hyperplasia&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Syndécane-2",
"description": "Quels traitements ciblent le Syndécane-2 ?\nLe Syndécane-2 peut-il être une cible thérapeutique ?\nY a-t-il des médicaments associés au Syndécane-2 ?\nComment les thérapies géniques affectent-elles le Syndécane-2 ?\nLe Syndécane-2 est-il impliqué dans des essais cliniques ?",
"url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Prostatic+Hyperplasia&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Syndécane-2",
"description": "Quelles complications peuvent survenir avec le Syndécane-2 ?\nLe Syndécane-2 est-il lié à des complications cardiovasculaires ?\nComment le Syndécane-2 affecte-t-il la réponse immunitaire ?\nY a-t-il des complications liées à la thérapie ciblée du Syndécane-2 ?\nLe Syndécane-2 influence-t-il la progression des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Prostatic+Hyperplasia&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Syndécane-2",
"description": "Quels sont les facteurs de risque pour le Syndécane-2 ?\nL'âge influence-t-il le Syndécane-2 ?\nLe stress a-t-il un impact sur le Syndécane-2 ?\nY a-t-il des prédispositions génétiques au Syndécane-2 ?\nL'environnement joue-t-il un rôle dans le Syndécane-2 ?",
"url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Prostatic+Hyperplasia&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de Syndécane-2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de tissus peuvent être utilisés pour évaluer les niveaux de Syndécane-2."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour le Syndécane-2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies et des analyses immunohistochimiques peuvent aider à diagnostiquer les anomalies."
}
},
{
"@type": "Question",
"name": "Le dosage sanguin est-il utile pour le Syndécane-2 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dosage sanguin peut fournir des informations sur les niveaux de Syndécane-2 dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés au Syndécane-2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs tumoraux et des cytokines peuvent être associés à l'expression de Syndécane-2."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests spécifiques pour le Syndécane-2 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests spécifiques d'immunofluorescence peuvent être utilisés pour détecter Syndécane-2."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction de Syndécane-2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles de l'adhésion cellulaire et des anomalies tissulaires."
}
},
{
"@type": "Question",
"name": "Le Syndécane-2 affecte-t-il la croissance tumorale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une expression anormale de Syndécane-2 peut influencer la croissance et la métastase tumorale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques associés au Syndécane-2 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques peuvent inclure des inflammations et des modifications dans la matrice extracellulaire."
}
},
{
"@type": "Question",
"name": "Le Syndécane-2 est-il lié à des maladies spécifiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est impliqué dans des maladies comme le cancer et certaines maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Comment le Syndécane-2 influence-t-il la signalisation cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il modifie la signalisation cellulaire en interagissant avec des récepteurs et des ligands."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies de Syndécane-2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain et la réduction des facteurs de risque associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages réguliers et une surveillance des maladies associées peuvent aider à la prévention."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le Syndécane-2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer l'expression de Syndécane-2 et la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il le Syndécane-2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer l'expression de Syndécane-2 et augmenter le risque de maladies."
}
},
{
"@type": "Question",
"name": "L'exercice physique a-t-il un impact sur le Syndécane-2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exercice régulier peut améliorer la santé cellulaire et potentiellement réguler Syndécane-2."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent le Syndécane-2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des anticorps monoclonaux peuvent être développés pour cibler Syndécane-2."
}
},
{
"@type": "Question",
"name": "Le Syndécane-2 peut-il être une cible thérapeutique ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en raison de son rôle dans la progression tumorale, il est une cible potentielle pour des traitements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments associés au Syndécane-2 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments expérimentaux ciblant la signalisation de Syndécane-2 sont en développement."
}
},
{
"@type": "Question",
"name": "Comment les thérapies géniques affectent-elles le Syndécane-2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies géniques peuvent corriger les anomalies d'expression de Syndécane-2 dans certaines pathologies."
}
},
{
"@type": "Question",
"name": "Le Syndécane-2 est-il impliqué dans des essais cliniques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques évaluent des traitements ciblant Syndécane-2 dans divers cancers."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le Syndécane-2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles de la cicatrisation et des métastases dans le cancer."
}
},
{
"@type": "Question",
"name": "Le Syndécane-2 est-il lié à des complications cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études suggèrent un lien entre Syndécane-2 et des complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment le Syndécane-2 affecte-t-il la réponse immunitaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une dysfonction de Syndécane-2 peut altérer la réponse immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications liées à la thérapie ciblée du Syndécane-2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent survenir avec les thérapies ciblées, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Le Syndécane-2 influence-t-il la progression des maladies ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une expression anormale peut accélérer la progression de certaines maladies, comme le cancer."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour le Syndécane-2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques, le tabagisme et l'obésité."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le Syndécane-2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter l'expression de Syndécane-2 et le risque de maladies associées."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le Syndécane-2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut influencer l'expression de Syndécane-2 et la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques au Syndécane-2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations génétiques peuvent augmenter le risque d'anomalies de Syndécane-2."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle dans le Syndécane-2 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut affecter l'expression de Syndécane-2."
}
}
]
}
]
}
Cribriform prostate cancer, found in both invasive cribriform carcinoma (ICC) and intraductal carcinoma (IDC), is an aggressive histological subtype that is associated with progression to lethal disea...
Partners of men diagnosed with prostate cancer face their own emotional struggles as they navigate additional caregiver responsibilities while concurrently adjusting to the diagnosis and coping with g...
This qualitative systematic review examined the unmet supportive care needs of partners affected by prostate cancer....
A meta-aggregation was conducted. Four electronic databases were searched using key words. The methodology followed the Joanna Briggs Institute for qualitative evidence synthesis. The review process f...
Twenty-one publications were included. A total of 239 findings and 32 categories were synthesized into 7 domains of unmet needs as experienced by partners. The domains of needs expressed by the partic...
There are gaps in clinical service support, despite routine clinical consultation with healthcare professionals. Partners may diminish their social networks to protect their husband at the cost to the...
Cancer organizations, policy makers, healthcare care professionals, and researchers are slowly making progress to acknowledge the unique support needs of partners affected by cancer. Healthcare profes...
Whether ultra-processed food consumption is associated with the risk of pancreatic cancer has not been determined. We performed a prospective study to fill this gap. A population-based cohort of 98 26...
Deep learning (DL)-based models have demonstrated an ability to automatically diagnose clinically significant prostate cancer (PCa) on MRI scans and are regularly reported to approach expert performan...
This systematic review was conducted in accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Studies investigating DL models for diagnosing c...
The final selection consisted of eight studies with a combined 7337 patients. The median study quality with CLAIM was 74.1% (IQR: 70.6-77.6). DL achieved an identical patient-level performance to the ...
DL models for the diagnosis of csPCa on MRI appear to approach the performance of experts but currently have a lower sensitivity compared to experienced radiologists. There is a need for studies with ...
Predicting the risk of side-specific extracapsular extension (ECE) is essential for planning nerve-sparing radical prostatectomy (RP) in patients with prostate cancer (PCa)....
To externally validate available models for prediction of ECE....
Sixteen models were assessed in a cohort of 737 consecutive PCa patients diagnosed via multiparametric magnetic resonance imaging (MRI)-targeted and systematic biopsies and treated with RP between Jan...
Model performance was evaluated in terms of discrimination using area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis (DCA)....
Overall, ECE was identified in 308/1474 (21%) prostatic lobes. Prostatic lobes with ECE had higher side-specific clinical stage on digital rectal examination and MRI, number of positive biopsy cores, ...
We report an external validation of models predicting ECE and identified the four with the best performance. These models should be applied for preoperative planning and patient counseling....
We validated several tools for predicting extension of prostate cancer outside the prostate gland. These tools can improve patient selection for surgery that spares nerves affecting recovery of sexual...
Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) are frequently poly-medicated due to age-related and androgen deprivation therapy (ADT)-derived comorbidities. In high-risk p...
We review the potential comorbidity burden of nmCRPC patients on the basis of epidemiologic studies on age-related comorbidities, the impact of ADT and specific studies analyzing this topic. Using the...
In high-risk nmCRPC patients to be treated with an ARI, careful multidisciplinary evaluation of potential DDIs is a fundamental component in the clinical-decision making. The lower potential for DDIs,...
Elevated prostate-specific antigen (PSA) levels often lead to unnecessary and possibly harmful transrectal ultrasound guided biopsy, e.g. when the biopsy is negative or contains only low-grade insigni...
Prostate cancer is the most common malignancy diagnosed in men. PI-RADS 3 lesions on multiparametric MRI, when histologically proven malignant, overwhelmingly represent prostatic adenocarcinoma. Prima...
We aimed to investigate the effect of available treatment modalities on primary treatment selection in patients with localized prostate cancer and that of introducing robotic surgery....
We retrospectively studied 12 061 patients diagnosed with localized prostate cancer between 2004 and 2018 from 21 institutions. These institutions were divided into five groups according to the availa...
Surgery, radiotherapy, androgen deprivation therapy, and active surveillance/watchful waiting were selected as primary treatment in 4115, 3621, 3188, and 821 patients, respectively, while the remainin...
Differences in available treatment modalities affect the selection of primary treatment for localized prostate cancer. Introduction of robotic surgery also has a strong influence on the number of pati...
DNA repair gene mutations are frequent in castration-resistant prostate cancer (CRPC), suggesting eligibility for poly(ADP-ribose) polymerase inhibitor (PARPi) treatment. However, therapy resistance i...